2.14
-0.02(-0.93%)
Currency In USD
| Previous Close | 2.16 |
| Open | 2.17 |
| Day High | 2.21 |
| Day Low | 2.07 |
| 52-Week High | 2.29 |
| 52-Week Low | 0.77 |
| Volume | 4.8M |
| Average Volume | 2.34M |
| Market Cap | 225.34M |
| PE | -7.13 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.79 |
| Moving Average 200 Days | 1.53 |
| Change | -0.02 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.04 as of October 18, 2025 at a share price of $2.14. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $829.46 as of October 18, 2025 at a share price of $2.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
GlobeNewswire Inc.
Oct 13, 2025 12:00 PM GMT
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemiaNEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic